Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: Retatrutide + Cagrilintide evidence and protocol review
Also known as: Reta/Cagri
This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.
Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.
Retatrutide + Cagrilintide combines Retatrutide + Cagrilintide into a single research protocol. Each component is independently studied; this entry summarizes the individual evidence base for the combination, since no unified safety/efficacy dataset covers the mixed formulation unless noted below. Retatrutide: Investigational triple GIP/GLP-1/glucagon receptor co-agonist; TRIUMPH Phase 3 program reported up to 28.3% mean weight loss at 80 weeks. Cagrilintide: Long-acting amylin receptor agonist; studied alone and combined with semaglutide (CagriSema) for weight management. This is a community-stacking combination assembled from two independently studied compounds rather than a pharmaceutical sponsor's dedicated fixed-dose combination program - no dedicated human combination trial exists for this exact pairing as of this writing.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence for individual components does not validate the exact mixed formulation. Component amounts, ratios, compatibility, sterility, and stability must be documented.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention Retatrutide + Cagrilintide or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.